- Supplier site
- Group of sites (click to zoom)
Scientist.com supplier network (site locations)
Research supplier
Ncardia
Ncardia is listed as a small business research supplier in the Scientist.com network, with 2 sites in 1 country and 2 service areas.
Sign in to Scientist.com to open this supplier in your organization's marketplace.
Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Services
What this research supplier says it provides, as listed in the Scientist.com network.
Type of company: Small business
Biomarkers
- Biomarker Discovery Identify a biomarker associated with disease progression of disease, effectiveness of therapy or diagnosis of disease or condition.
- Biomarker Services Evaluating normal/abnormal biological conditions and characteristics within the body
- Cell Viability Measure changes in cell number, cell division, DNA content or a cell metabolism marker such as ATP levels.
- Cytokine Release Assay Use in vivo or in vitro assays to detect unregulated or excessive release of pro-inflammatory cytokines.
- Flow Cytometry Identify fluorescently-labeled cells or physically separate cells from a larger population using biomarkers.
- Immunophenotyping Separate cell types based on their expression of biomarkers or based on their individual and unique expression patterns.
Show all 9 in Biomarkers
- Immunostaining Use labeled antibodies to detect proteins or other antigens in cells or tissues.
- Pharmacodynamic Biomarkers Discovery Identify candidate biomarkers indicative of the therapeutic outcome of a drug-target interaction.
- Stem Cell Analysis Assess hematopoietic, neural and mesenchymal cell progenitor proliferation and differentiation.
Cell Culture and Characterization
- 3D Cell Culture Use a scaffold-based or scaffold-free format to grow three dimensional cell and tissue structures.
- Adherent Cell Culture Grow monolayers of anchorage-dependent cells.
- Cell Culture Culture primary or immortalized cell lines.
- Cell Transfection Produce, package and optimize transfection of your siRNA or DNA construct.
- Gene-Edited iPSCs Disease Models Use gene-edited iPSCs to model human diseases.
- Induced Pluripotent Stem (iPS) Cell Reprogramming Generate induced pluripotent stem cells from adult somatic cells.
Show all 7 in Cell Culture and Characterization
- Stem Cell Differentiation Acquire specialized cells from differentiated stem cells.
Show all 65 services
Disease Models
- Cardiovascular Models Test the therapeutic efficacy of drug candidates in cardiovacular disease models.
- Ischemia Models Measure therapeutic endpoints in animal models of ischemia.
- Neuroscience Models Test therapeutic efficacy of drug candidate in neurological disease model.
- Parkinson's Disease Models Measure therapeutic endpoints in animal models of Parkinson's disease.
Drug Development
- Safety Pharmacology Consulting Consulting services that help with the detection of potential undesirable pharmacodynamic effects of chemical entities on physiological functions.
General in vivo Toxicology
- Mammalian Toxicology Use toxicity testing models to carry out required FDA or REACH safety testing.
Human Biological Samples
- Biospecimen Finder Explore listings of Human Biological Samples from the suppliers on the scientist.com HBS database
- FRBESaHBS Request human biosamples including tissues, blood, serum, bone marrow, and tissue microarrays.
- HBS: Human Biological Samples Request human biosamples including tissues, blood, serum, bone marrow, tissue microarrays, etc.
- HBS: Human Biological Samples - VMS Request human biosamples including tissues, blood, serum, bone marrow, tissue microarrays, etc.
- Human iPSC's For requesting human sourced induced pluripotent stem cells.
In Vitro Assays
- 3D Cell Microscopy Assay Investigate cellular and subcellular events in three dimensional 3D cultures by using fluorescence microscopy.
- Apoptosis Assays Detect apoptotic events that lead to programmed cell death.
- Apoptotic Cell Staining Detect apoptotic cells in culture.
- Assay Development Construct or create new assays or modify existing ones.
- Caspase Assay Detect early to mid stage apoptosis or differentiate apoptosis from necrosis.
- Cell Based Assays Apply compounds to cells and test for cellular phenotypes and effects on gene expression
Show all 11 in In Vitro Assays
- Cell Proliferation Measure cell number, cell viability and cell division.
- High Content Screening Analyze whole cells or components of cells with simultaneous readout of several parameters.
- HTS Assay Development Develop assays to use in high throughput screening.
- Inflammation Assays Identify and validate pro- and anti-inflammatory molecules, recruitment inhibitors and chemotaxis modulators.
- Phenotype Assays Measure effects of drug candidate on the morphology or function of cells and whole animals.
In Vitro Pharmacology
- Calcium Channel Assays Use biochemical, cell-based or in vivo assays to measure calcium channel activity.
- G-Protein Coupled Receptor (GPCR) Assays Detect ligand binding, receptor dimerization and downstream signal transduction events.
- High Throughput Screening Conduct millions of chemical, genetic or pharmacological tests in a short period of time.
- In Vitro Cardiovascular Models Measure stimulation and inhibition of lipolysis, adipogenesis and endothelial cell migration.
- In Vitro Disease Models Screen pre-clinical candidates without the use of live animals.
- In Vitro Excitotoxicity Models Use in vitro models to measure therapeutic endpoints associated with excitotoxic pathology.
Show all 12 in In Vitro Pharmacology
- In Vitro Hypoxia Models Use in vitro models to measure therapeutic endpoints associated with hypoxia.
- In Vitro Neural Models Use cultured neurons, neuronal progenitor cells and stem cell differentiation to create cellular models of neurological disease.
- Ion Channels Use fluorometry, electrophysiology and radiometric binding assays to measure ion channel activity.
- Potassium Channel Assays Use biochemical, cell-based or in vivo assays to measure potassium channel activity.
- Sodium Channel Assays Use biochemical, cell-based or in vivo assays to measure sodium channel activity.
- Target Validation Demonstrate that modification of target activity has potential therapeutic benefits.
In Vitro Toxicology
- Cardiac Channels Measure the arrhythmia producing potential of test compounds.
- Cardiomyocyte Toxicity Assess cytotoxic effects of pre-clinical compounds on cardiomyocytes.
- Cardiotoxicity Evaluate the effect of a compound on heart electrophysiology and muscle function.
- Cardiovascular Toxicology Measure the toxic effects of pre-clinical compounds.
- Cytotoxicity Test for effects on cell viability and proliferation
- Cytotoxicity Testing Determine whether a cosmetic product or ingredient is toxic to in vitro cell cultures.
Show all 9 in In Vitro Toxicology
- Endothelial Cell Toxicity Assess the cytotoxic effects of pre-clinical compounds on the vascular system.
- hERG Inhibition Measure the arrhythmia-producing potential of test compounds.
- Microelectrode Array Cardiotoxicity Assays Use microelectrode array to measure cardiotoxicity-related activities.
Nanotechnology
- Liposomes Create artificial spherical vesicles that can be used as a vehicle for administration of drugs.
Safety Pharmacology
- Microelectrode Array Neurotoxicity Assays Use microelectrode array to measure neurotoxicity-related activities.
- Off Target Effects Assess toxicities by body weight, clinical chemistry, hematology, urinalysis and terminal necropsy and pathology.
- Safety Pharmacology Assess the impact of a therapeutic for human use on vital organ systems before first-in-man drug testing.
Other services
- In Vitro Neurodegenerative Disease Platform Use an IVND platform to screen different compounds/drugs in a finely controlled synaptopathies scenario.
- New Request
Service areas:
Where it operates
Sites by country, with the cities in each.
-
Netherlands 2 sites
About this supplier
In the supplier's own words, as listed in the Scientist.com network.
The business objective of Axiogenesis lies in the area of pre-clinical biotechnology, specifically in the production of stem cell-based assays that enable drug development. These innovative and proprietary assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency. At present the main focus is heart muscle disease (cardiomyopathy). Since early 2008, the first products of Axiogenesis have been actively marketed and are already generating significant turnovers. This range of products has been further developed employing...
Show the full description
The business objective of Axiogenesis lies in the area of pre-clinical biotechnology, specifically in the production of stem cell-based assays that enable drug development. These innovative and proprietary assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency. At present the main focus is heart muscle disease (cardiomyopathy).
Since early 2008, the first products of Axiogenesis have been actively marketed and are already generating significant turnovers.
This range of products has been further developed employing groundbreaking human induced Pluripotent Stem cell (iPS) technology. Through in-house development of human iPS technology, the next product generation of murine embryonic stem cells has beencomplemented with human iPS cell-derived tissues.
With this technology it is possible to reverse-differentiate (or de-differentiate) adult human cells (e.g., skin or blood cells) to an artificial embryonic state. Using proprietary technology, Axiogenesis then forward-differentiates these into pure organ-specific cells and defined tissues. Proof of concept of this two-step method was established in-house during November 2008 and the first human, organ-specific iPS cells were launched in 2012.
A range of tissue models (including heart, liver and nerve) will be produced through the proliferation and differentiation of genetically modified stem cells. These are used to test efficacy and potential adverse side effects of drug candidates.
Increased drug development efficiency, with the use of Axiogenesis technology, is achieved through:
- Earlier selections against drug candidates that will have high adverse side affects or do not have a therapeutic effect.
- Early selection and fast tracking of drug candidates with high efficacy and low side effects.
- Partial substitution of costly animal studies.
- Reduction of the time taken for preclinical studies.
- Extension of marketing exclusivity gained through a shorter drug development cycle, resulting in a longer time from market authorization until patent protection is lost.
Furthermore the system lends itself to product line extension through rapid testing of side effect profiles and improvements in efficacy of modified compounds or through the identification of novel indications of existing active pharmaceutical ingredients (APIs).
- Professional associations
- LRIG, MassBio, Society of Laboratory Automation and Screening (SLAS), SOT
- Website
- www.ncardia.com
Work with Ncardia on Scientist.com
For prices, more details, or to contact Ncardia, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.